Investment Thesis
Oscar Health demonstrates strong profitability margins (15.2% operating, 14.6% net) and exceptional free cash flow generation (2.6B at 56.2% margin), supported by a fortress balance sheet with conservative leverage (0.26x D/E). However, critical red flags emerge from data inconsistencies: net income growth of 0.0% contradicts claimed 40,824% revenue growth, and severe EPS decline (-1,790%) despite flat earnings indicates substantial shareholder dilution, suggesting underlying operational or structural headwinds.
Strengths
- Exceptional profitability metrics with 40.8% ROE and 14.6% net margin demonstrating strong unit economics
- Outstanding free cash flow generation of 2.6B with 56.2% FCF conversion rate, indicating high-quality earnings
- Conservative balance sheet with 0.26x debt/equity ratio, 4.8B cash position, and 119.3x interest coverage providing financial flexibility
Risks
- Net income stagnation (0.0% YoY growth) despite massive claimed revenue growth suggests potential margin compression, acquisition dilution, or data quality issues
- Catastrophic EPS decline (-1,790%) indicating severe shareholder dilution that destroys per-share economics regardless of absolute profit levels
- Abnormally tight current ratio of 1.09x with high leverage embedded in liabilities despite strong absolute cash position suggests operational cash flow dependency
Key Metrics to Watch
- Reconciliation of revenue growth vs. net income growth and underlying driver analysis (pricing, mix, or costs)
- Share count trends and dilution sources over recent quarters relative to equity issuance
- Medical loss ratio and unit economics per member in core markets
Financial Metrics
Revenue
4.6B
Net Income
679.0M
EPS (Diluted)
$2.07
Free Cash Flow
2.6B
Total Assets
9.3B
Cash
4.8B
Profitability Ratios
Gross Margin
N/A
Operating Margin
15.2%
Net Margin
14.6%
ROE
40.8%
ROA
7.3%
FCF Margin
56.2%
Balance Sheet & Liquidity
Current Ratio
1.09x
Quick Ratio
1.09x
Debt/Equity
0.26x
Debt/Assets
82.1%
Interest Coverage
119.30x
Long-term Debt
430.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T11:47:45.389485 |
Data as of: 2026-03-31 |
Powered by Claude AI